Clinical Trial Update: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating odronextamab for relapsed or refractory diffuse large B-cell lymphoma before and after CAR T-cell therapy is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• Odronextamab (odronextamab)

Snippet

Sponsor: Joseph Tuscano | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING